Psychedelic Therapeutics Market Size, Share & Trends Analysis Report, by Origin of Substance (Natural and Synthetic), Type of Psychedelic Substance (Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin), Target Disease Indications (Depression and Anxiety Disorders, Pain Disorders, Sleep Related Disorders and Trauma), Route of Administration, By Region, Forecasts, 2025-2034
Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034 at a 15.6 % CAGR during the forecast period for 2025-2034.
Psychedelic medicines are also referred to as hallucinogenic. Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.
The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth.
In 2023, North America led the market. Major determinants, such as the increase in the frequency of depression and other mental diseases and the rapid advancement of research, are driving the market growth. The population's increased awareness of anxiety and mental health is anticipated to stimulate regional growth further. The Asia-Pacific region is anticipated to see a considerable growth rate over the projected period as a result of the growing awareness of mental diseases and the expansion of healthcare infrastructure.
Market Segmentation
The global psychedelic therapeutics market is segmented on the basis of Origin of Psychedelic Substance, Type of Psychedelic Substance, Target Therapeutic Area and region. Based on the Origin of Psychedelic Substance, the market is divided into Synthetic Substances and Natural Substances. On the basis of Type of Psychedelic Substance, the market is divided in to GHB, Ketamine, MDMA and Psilocybin.
On the basis of Target Therapeutic Area, the market is divided into Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
Competitive Landscape
Some major key players in the Psychedelic Therapeutics Market:
- Celon Pharma S.A.,
- MAPS Public Benefit,
- MindMed,
- Janssen Pharmaceuticals,
- iX Biopharma Ltd,
- Jazz Pharmaceutical,
- Avadel,
- Pharmaceuticals plc,
- NeuroRx, Inc.,
- Douglas Pharmaceuticals Limited,
- The Emmes,
- Company, LLC,
- CaaMTech,
- COMPASS Pathways plc,
- Eleusis Benefit Corporation,
- AWAKN Life Sciences Inc,
- Psilera Bioscience,
- Braxia Scientific Corp.,
- Mindset Pharma,
- BetterLife Pharma,
- Cybin,
- CB Therapeutics,
- Numinus Wellness,
- Mydecine Innovations Group,
- Optimi Health,
- PharmaTher,
- Field Trip Health,
- ATAI Life Sciences,
- GH Research,
- Seelos Therapeutics,
- Small Pharma,
- Bright Minds Biosciences,
- Incannex Health,
- PsyBio Therapeutics,
- Universal Ibogaine,
- Levitee Labs,
- Mind Cure Health,
- Novamind,
- Clearmind Medicine,
- MYND Life Science,
- Wesana Health,
- Psyched Wellness,
- HAVN Life Sciences,
- Tryp Therapeutics,
- Psyence Group,
- Silo Pharma,
- Core One Labs,
- M2Bio Sciences,
- Neonmind Biosciences,
- Delic Corp,
- Nova Mentis Life Science,
- Beckley Psytech,
- Delix Therapeutics,
- Diamond Therapeutics,
- Tactogen,
- Psygen Labs Inc.,
- Bexson Biomedical,
- Eleusis Biotech,
- Psilera Biosceince,
- Octarine Bio,
- Heading Health,
- MAPS Public Benefit Corporation (PBC),
- Aphrodite Health,
- Terran Biosciences,
- Mycrodose Therapeutics,
- Reset Pharma,
- Clerkenwell Health,
- Alvarius Pharmaceuticals,
- Ceruvia Lifesciences,
- Other Prominent Player.
Psychedelic Therapeutics Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.2 Billion |
| Revenue Forecast In 2034 | USD 9.6 Billion |
| Growth Rate CAGR | CAGR of 15.6 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type of Psychedelic Substance, Origin of Psychedelic Substance, Target Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation Of Psychedelic Therapeutics Market
Psychedelic Therapeutics Market- By Origin of Substance
- Natural
- Synthetic
Psychedelic Therapeutics Market- By Type of Psychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
Psychedelic Therapeutics Market- By Target Disease Indications
- Depression and Anxiety Disorders
- Pain Disorders
- Sleep-Related Disorders
- Trauma
Psychedelic Therapeutics Market- By Route of Administration
- Oral
- Intravenous
- Intranasal
- Sublingual
Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region
Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- U.S.
- Canada
Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034
Psychedelic Therapeutics Market is expected to grow at a 15.6% CAGR during the forecast period for 2025-2034
Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx,
Type of Psychedelic Substance, Origin of Psychedelic Substance and Target Therapeutic Area are the key segments of the Psychedelic Therapeutics Market
North American region is leading the Psychedelic Therapeutics Market.